ReviseNOW: Guidance for psychiatrists

Psychopharmacology

National guidance

Below are links to useful guidelines on this topic. Clicking on a document title will open a new window on the external website. Access to some documents may be restricted. Access to these articles is not part of any Superego Cafe subscription.

• Stop smoking service delivery and monitoring guidance 2011/12
  DOH 2011
• Alzheimer’s disease - donepezil, galantamine, rivastigmine and memantine
  NICE 2011
• Aripiprazole for schizophrenia in people aged 15 to 17 years
  NICE 2011
• Safer lithium therapy
  2009
• Evidence-based Guidelines for Treating Bipolar Disorder
  BAP 2009
• Evidence-based guidelines for treating depressive disorders with antidepressants
  BAP 2008
• Alzheimer's disease - donepezil, galantamine, rivastigmine (review) and memantine
  NICE 2007
• Varenicline for smoking cessation
  NICE 2007
• Naltrexone for the management of opioid dependence
  NICE 2007
• CR142. Use of licensed medicines for unlicensed applications in psychiatric practice
  RCPsych 2007
• Methadone and buprenorphine for managing opioid dependence
  NICE 2007
• Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology
  BAP 2006
• http://www.rcpsych.ac.uk/publications/collegereports/cr/cr141.aspx
  RCPsych 2006
• Attention deficit hyperactivity disorder (ADHD) - methylphenidate, atomoxetine and dexamfetamine (review)
  NICE 2006
• Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults
  BAP 2006